Insider Selling: Jazz Pharmaceuticals (NASDAQ:JAZZ) Director Sells $490,000.00 in Stock

Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) Director Bruce Cozadd sold 3,500 shares of the firm’s stock in a transaction dated Friday, October 3rd. The shares were sold at an average price of $140.00, for a total transaction of $490,000.00. Following the completion of the sale, the director owned 408,826 shares of the company’s stock, valued at $57,235,640. The trade was a 0.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at this link.

Jazz Pharmaceuticals Price Performance

Shares of JAZZ stock opened at $139.48 on Monday. Jazz Pharmaceuticals PLC has a 1 year low of $95.49 and a 1 year high of $148.06. The company has a current ratio of 1.62, a quick ratio of 1.37 and a debt-to-equity ratio of 1.17. The firm’s 50 day moving average is $123.75 and its 200-day moving average is $115.49. The firm has a market capitalization of $8.46 billion, a price-to-earnings ratio of -20.73, a PEG ratio of 8.65 and a beta of 0.28.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings results on Tuesday, August 5th. The specialty pharmaceutical company reported ($8.25) earnings per share for the quarter, missing analysts’ consensus estimates of ($5.61) by ($2.64). Jazz Pharmaceuticals had a negative net margin of 9.91% and a positive return on equity of 5.02%. The company had revenue of $1.05 billion during the quarter, compared to analyst estimates of $1.05 billion. During the same period in the prior year, the business earned $5.30 EPS. The business’s revenue for the quarter was up 2.1% on a year-over-year basis. Jazz Pharmaceuticals has set its FY 2025 guidance at 4.800-5.600 EPS. Sell-side analysts forecast that Jazz Pharmaceuticals PLC will post 16.96 EPS for the current fiscal year.

Institutional Trading of Jazz Pharmaceuticals

A number of institutional investors have recently modified their holdings of JAZZ. GAMMA Investing LLC grew its holdings in shares of Jazz Pharmaceuticals by 30.7% during the third quarter. GAMMA Investing LLC now owns 655 shares of the specialty pharmaceutical company’s stock worth $86,000 after buying an additional 154 shares in the last quarter. China Universal Asset Management Co. Ltd. boosted its position in Jazz Pharmaceuticals by 1.6% during the 2nd quarter. China Universal Asset Management Co. Ltd. now owns 12,383 shares of the specialty pharmaceutical company’s stock worth $1,314,000 after acquiring an additional 201 shares during the last quarter. Thrivent Financial for Lutherans raised its holdings in shares of Jazz Pharmaceuticals by 38.1% in the second quarter. Thrivent Financial for Lutherans now owns 19,720 shares of the specialty pharmaceutical company’s stock valued at $2,093,000 after purchasing an additional 5,440 shares during the last quarter. Marex Group plc bought a new stake in shares of Jazz Pharmaceuticals in the second quarter worth $610,000. Finally, State of Wyoming lifted its position in shares of Jazz Pharmaceuticals by 21.4% in the second quarter. State of Wyoming now owns 4,029 shares of the specialty pharmaceutical company’s stock worth $428,000 after purchasing an additional 709 shares in the last quarter. 89.14% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

JAZZ has been the topic of several recent research reports. The Goldman Sachs Group raised their price target on Jazz Pharmaceuticals from $162.00 to $185.00 and gave the company a “buy” rating in a report on Friday, August 29th. Needham & Company LLC reiterated a “buy” rating and set a $202.00 price target on shares of Jazz Pharmaceuticals in a research report on Thursday, August 28th. Zacks Research raised shares of Jazz Pharmaceuticals from a “strong sell” rating to a “hold” rating in a research note on Friday, August 15th. Deutsche Bank Aktiengesellschaft assumed coverage on shares of Jazz Pharmaceuticals in a research note on Tuesday, July 15th. They issued a “buy” rating and a $152.00 price objective on the stock. Finally, Royal Bank Of Canada lifted their target price on shares of Jazz Pharmaceuticals from $145.00 to $151.00 and gave the stock an “outperform” rating in a report on Thursday, August 28th. Fourteen equities research analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company’s stock. According to MarketBeat.com, Jazz Pharmaceuticals has a consensus rating of “Moderate Buy” and a consensus target price of $178.93.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc identifies, develops, and commercializes pharmaceutical products for unmet medical needs in the United States, Europe, and internationally. The company offers Xywav for cataplexy or excessive daytime sleepiness (EDS) with narcolepsy and idiopathic hypersomnia; Xyrem to treat cataplexy or EDS with narcolepsy; Epidiolex for seizures associated with Lennox-Gastaut and Dravet syndromes, or tuberous sclerosis complex; Zepzelca to treat metastatic small cell lung cancer, or with disease progression on or after platinum-based chemotherapy; Rylaze for acute lymphoblastic leukemia or lymphoblastic lymphoma; Enrylaze to treat acute lymphoblastic leukemia and lymphoblastic lymphoma; Defitelio to treat severe hepatic veno-occlusive disease; and Vyxeos for newly-diagnosed therapy-related acute myeloid leukemia.